Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Allosteric disulphide bonds as reversible mechano-sensitive switches that control protein functions in the vasculature.

Passam FJ, Chiu J.

Biophys Rev. 2019 Jun;11(3):419-430. doi: 10.1007/s12551-019-00543-0. Epub 2019 May 14. Review.

2.

Functional Assays of Thiol Isomerase ERp5.

Dupuy A, Passam F.

Methods Mol Biol. 2019;1967:149-163. doi: 10.1007/978-1-4939-9187-7_9.

PMID:
31069769
3.

Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia.

Perdomo J, Leung HHL, Ahmadi Z, Yan F, Chong JJH, Passam FH, Chong BH.

Nat Commun. 2019 Mar 21;10(1):1322. doi: 10.1038/s41467-019-09160-7.

4.

Protein disulfide isomerase regulation by nitric oxide maintains vascular quiescence and controls thrombus formation.

Bekendam RH, Iyu D, Passam F, Stopa JD, De Ceunynck K, Muse O, Bendapudi PK, Garnier CL, Gopal S, Crescence L, Chiu J, Furie B, Panicot-Dubois L, Hogg PJ, Dubois C, Flaumenhaft R.

J Thromb Haemost. 2018 Nov;16(11):2322-2335. doi: 10.1111/jth.14291. Epub 2018 Oct 12.

PMID:
30207066
5.

Mechano-redox control of integrin de-adhesion.

Passam F, Chiu J, Ju L, Pijning A, Jahan Z, Mor-Cohen R, Yeheskel A, Kolšek K, Thärichen L, Aponte-Santamaría C, Gräter F, Hogg PJ.

Elife. 2018 Jun 22;7. pii: e34843. doi: 10.7554/eLife.34843.

6.

Quantification of NETs-associated markers by flow cytometry and serum assays in patients with thrombosis and sepsis.

Lee KH, Cavanaugh L, Leung H, Yan F, Ahmadi Z, Chong BH, Passam F.

Int J Lab Hematol. 2018 Aug;40(4):392-399. doi: 10.1111/ijlh.12800. Epub 2018 Mar 9.

PMID:
29520957
7.

Autoregulation of von Willebrand factor function by a disulfide bond switch.

Butera D, Passam F, Ju L, Cook KM, Woon H, Aponte-Santamaría C, Gardiner E, Davis AK, Murphy DA, Bronowska A, Luken BM, Baldauf C, Jackson S, Andrews R, Gräter F, Hogg PJ.

Sci Adv. 2018 Feb 28;4(2):eaaq1477. doi: 10.1126/sciadv.aaq1477. eCollection 2018 Feb.

8.

Βeta 2-glycoprotein I protects mice against gram-negative septicaemia in a sexually dimorphic manner.

El-Assaad F, Qi M, Gordon AK, Qi J, Dong S, Passam F, Weaver JC, Giannakopoulos B, Krilis SA.

Sci Rep. 2017 Aug 15;7(1):8201. doi: 10.1038/s41598-017-07945-8.

9.

Protein Disulfide Isomerase in Thrombosis.

Chiu J, Passam F, Butera D, Hogg PJ.

Semin Thromb Hemost. 2015 Oct;41(7):765-73. doi: 10.1055/s-0035-1564047. Epub 2015 Sep 26. Review.

PMID:
26408919
10.

Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its b'x Domain.

Lin L, Gopal S, Sharda A, Passam F, Bowley SR, Stopa J, Xue G, Yuan C, Furie BC, Flaumenhaft R, Huang M, Furie B.

J Biol Chem. 2015 Sep 25;290(39):23543-52. doi: 10.1074/jbc.M115.666180. Epub 2015 Aug 3.

11.

Both platelet- and endothelial cell-derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis.

Passam FH, Lin L, Gopal S, Stopa JD, Bellido-Martin L, Huang M, Furie BC, Furie B.

Blood. 2015 Apr 2;125(14):2276-85. doi: 10.1182/blood-2013-12-547208. Epub 2015 Jan 26.

12.

Identification of ML359 as a Small Molecule Inhibitor of Protein Disulfide Isomerase.

Khodier C, VerPlank L, Nag PP, Pu J, Wurst J, Pilyugina T, Dockendorff C, Galinski CN, Scalise AA, Passam F, van Hessem L, Dilks J, Kennedy DR, Flaumenhaft R, Palmer MAJ, Dandapani S, Munoz B, Schrieber SL.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Apr 12 [updated 2014 Sep 18].

13.

Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents.

Jasuja R, Passam FH, Kennedy DR, Kim SH, van Hessem L, Lin L, Bowley SR, Joshi SS, Dilks JR, Furie B, Furie BC, Flaumenhaft R.

J Clin Invest. 2012 Jun;122(6):2104-13. doi: 10.1172/JCI61228. Epub 2012 May 8.

14.

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Owens AP 3rd, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, Tobias PS, Curtiss LK, Daugherty A, Kirchhofer D, Luyendyk JP, Moriarty PM, Nagarajan S, Furie BC, Furie B, Johns DG, Temel RE, Mackman N.

J Clin Invest. 2012 Feb;122(2):558-68. doi: 10.1172/JCI58969. Epub 2012 Jan 3.

15.

Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I.

Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA.

J Thromb Haemost. 2011 Jul;9 Suppl 1:275-82. doi: 10.1111/j.1538-7836.2011.04301.x. Review.

16.

Redox control of β2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1.

Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA.

J Thromb Haemost. 2010 Aug;8(8):1754-62. doi: 10.1111/j.1538-7836.2010.03944.x.

17.

Beta 2 glycoprotein I is a substrate of thiol oxidoreductases.

Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA.

Blood. 2010 Sep 16;116(11):1995-7. doi: 10.1182/blood-2010-02-271494. No abstract available.

18.

In vivo modulation of angiogenesis by beta 2 glycoprotein I.

Passam FH, Qi JC, Tanaka K, Matthaei KI, Krilis SA.

J Autoimmun. 2010 Nov;35(3):232-40. doi: 10.1016/j.jaut.2010.06.013. Epub 2010 Jul 24.

PMID:
20655705
19.

Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury.

Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, Qi M, Yu P, Yu DM, Hogg PJ, Krilis SA.

Blood. 2010 Sep 16;116(11):1961-70. doi: 10.1182/blood-2009-04-215335. Epub 2010 Jun 15.

20.

Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma.

Passam FH, Alexandrakis MG, Kafousi M, Fotinou M, Darivianaki K, Tsirakis G, Roussou PA, Stathopoulos EN, Siafakas NM.

Pathol Res Pract. 2009;205(1):11-20. doi: 10.1016/j.prp.2008.07.007. Epub 2008 Oct 23.

PMID:
18950958
21.

How we diagnose the antiphospholipid syndrome.

Giannakopoulos B, Passam F, Ioannou Y, Krilis SA.

Blood. 2009 Jan 29;113(5):985-94. doi: 10.1182/blood-2007-12-129627. Epub 2008 Aug 28. Review.

22.

Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain.

Yu P, Passam FH, Yu DM, Denyer G, Krilis SA.

J Thromb Haemost. 2008 Jul;6(7):1215-23. doi: 10.1111/j.1538-7836.2008.03000.x. Epub 2008 Jul 1.

23.

Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment.

Passam FH, Sfiridaki A, Pappa C, Kyriakou D, Petreli E, Roussou PA, Alexandrakis MG.

Int J Lab Hematol. 2008 Feb;30(1):17-25. doi: 10.1111/j.1365-2257.2006.00890.x.

PMID:
18190463
24.

Current concepts on the pathogenesis of the antiphospholipid syndrome.

Giannakopoulos B, Passam F, Rahgozar S, Krilis SA.

Blood. 2007 Jan 15;109(2):422-30. Epub 2006 Sep 19. Review.

25.

Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach.

Passam F, Tachynopoulou V, Skoumi D, Tsompanakou A, Stavropoulos-Giokas A, Vadikolia C, Anagnostopoulos A, Paterakis G.

Ann Hematol. 2006 Nov;85(11):795-805. Epub 2006 Jul 27.

PMID:
16871389
26.

Thymoma with immunodeficiency (Good's syndrome): review of the literature apropos three cases.

Miyakis S, Pefanis A, Passam FH, Christodulakis GR, Roussou PA, Mountokalakis TD.

Scand J Infect Dis. 2006;38(4):314-9.

PMID:
16718939
27.

Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis.

Passam FH, Alexandrakis MG, Moschandrea J, Sfiridaki A, Roussou PA, Siafakas NM.

Int J Immunopathol Pharmacol. 2006 Jan-Mar;19(1):161-70.

PMID:
16569354
28.

Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production.

Zachou K, Rigopoulou EI, Tsikrikoni A, Alexandrakis MG, Passam F, Kyriakou DS, Stathakis NE, Dalekos GN.

J Autoimmun. 2005 Dec;25(4):283-8. Epub 2005 Oct 20.

PMID:
16242912
29.

Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density.

Alexandrakis MG, Passam FH, Pappa CA, Damilakis J, Tsirakis G, Kandidaki E, Passam AM, Stathopoulos EN, Kyriakou DS.

Int J Immunopathol Pharmacol. 2005 Apr-Jun;18(2):287-95.

PMID:
15888251
30.

The assessment of proliferating cell nuclear antigen immunostaining in myelodysplastic syndromes and its prognostic significance.

Alexandrakis MG, Passam FH, Dambaki K, Passam AM, Nalbanti F, Stathopoulos ES, Kyriakou DS.

Eur J Histochem. 2005 Jan-Mar;49(1):27-32.

PMID:
15823791
31.

Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis.

Tsikrikoni A, Kyriakou DS, Rigopoulou EI, Alexandrakis MG, Zachou K, Passam F, Dalekos GN.

J Hepatol. 2005 Mar;42(3):393-9.

PMID:
15710223
32.

Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes.

Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki C, Katrinakis G, Tsirakis G, Konsolas J, Stathopoulos EN.

J Mol Histol. 2004 Nov;35(8-9):857-63.

PMID:
15609099
33.

Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their prognostic significance.

Passam FH, Tsirakis G, Boula A, Fragou A, Consolas I, Alegakis A, Kyriakou DS, Alexandrakis MG.

Clin Lab Haematol. 2004 Dec;26(6):391-5.

PMID:
15595996
34.

Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.

Alexandrakis MG, Passam FJ, Ganotakis E, Dafnis E, Dambaki C, Konsolas J, Kyriakou DS, Stathopoulos E.

Clin Chem Lab Med. 2004;42(10):1122-6.

PMID:
15552270
35.

Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.

Alexandrakis MG, Passam FH, Pappa CA, Sfiridaki K, Tsirakis G, Damilakis J, Stathopoulos EN, Kyriakou DS.

Leuk Res. 2005 Jan;29(1):41-6.

PMID:
15541473
36.

Clinical significance of circulating endothelial adhesion molecules (sE-selectin and sICAM) in untreated multiple myeloma patients.

Alexandrakis MG, Passam FH, Sfiridaki K, Kafarakis P, Karydi E, Liapi D, Perisinakis K, Kyriakou DS.

Clin Chim Acta. 2004 Nov;349(1-2):39-43.

PMID:
15469853
37.

Intestinal ischemia as the first manifestation of vasculitis.

Passam FH, Diamantis ID, Perisinaki G, Saridaki Z, Kritikos H, Georgopoulos D, Boumpas DT.

Semin Arthritis Rheum. 2004 Aug;34(1):431-41. Review.

PMID:
15305242
38.

The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.

Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN.

J Clin Pathol. 2004 Aug;57(8):856-60.

39.

Laboratory tests for the antiphospholipid syndrome: current concepts.

Passam F, Krilis S.

Pathology. 2004 Apr;36(2):129-38. Review.

PMID:
15203748
40.

Pleural effusions in hematologic malignancies.

Alexandrakis MG, Passam FH, Kyriakou DS, Bouros D.

Chest. 2004 Apr;125(4):1546-55. Review.

PMID:
15078773
41.

Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines.

Alexandrakis MG, Passam FH, Sfiridaki A, Pappa CA, Moschandrea JA, Kandidakis E, Tsirakis G, Kyriakou DS.

Int J Biol Markers. 2004 Jan-Mar;19(1):52-7.

PMID:
15077927
42.

Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity.

Alexandrakis MG, Passam FH, Pappa CA, Dambaki C, Sfakiotaki G, Alegakis AK, Kyriakou DS, Stathopoulos E.

Int J Immunopathol Pharmacol. 2004 Jan-Apr;17(1):49-56.

PMID:
15000866
43.

Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.

Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E.

Am J Clin Oncol. 2004 Feb;27(1):8-13.

PMID:
14758126
44.

Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.

Alexandrakis MG, Passam FH, Kyriakou DS, Christophoridou AV, Perisinakis K, Hatzivasili A, Foudoulakis A, Castanas E.

Am J Hematol. 2004 Feb;75(2):101-6.

45.

Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.

Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P, Kyriakou DS.

Leuk Res. 2004 Mar;28(3):259-66.

PMID:
14687621
46.

Microsatellite DNA instability and loss of heterozygosity in bronchial asthma.

Paraskakis E, Sourvinos G, Passam F, Tzanakis N, Tzortzaki EG, Zervou M, Spandidos D, Siafakas NM.

Eur Respir J. 2003 Dec;22(6):951-5.

47.

Elevated serum angiogenin in multiple myeloma.

Alexandrakis MG, Passam FH, Sfiridaki A, Kyriakou DS, Petreli E, Roussou P.

Hematol J. 2003;4(6):454-5. No abstract available.

PMID:
14671622
48.

Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis.

Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis NE, Dalekos GN.

J Hepatol. 2003 Nov;39(5):679-85.

PMID:
14568247
50.

Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis.

Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, Kyriakou DS.

Am J Clin Oncol. 2003 Apr;26(2):135-40.

PMID:
12714883

Supplemental Content

Loading ...
Support Center